Table 1.

Patient clinicopathologic characteristics in Stockholm and multi-institutional cohorts

Stockholm untreated (n = 283)Stockholm TAM-treated (n = 317)Multi-institutional (n = 358)
Age at surgery, y
 <504 (1%)2 (<1%)108 (30%)
 50–5992 (33%)89 (28%)113 (32%)
 60–69178 (63%)214 (68%)93 (26%)
 ≥709 (3%)12 (4%)44 (12%)
Tumor size
 ≤20 mm230 (81%)259 (82%)237 (66%)
 >20 mm51 (18%)55 (17%)121 (34%)
 Unknown2 (1%)3 (1%)0
Tumor grade
 Well69 (24%)67 (21%)82 (23%)
 Moderate175 (62%)211 (67%)219 (61%)
 Poor39 (14%)39 (12%)57 (16%)
PR status
 Negative73 (26%)72 (23%)NA
 Positive182 (64%)220 (69%)
 Unknown28 (10%)25 (8%)
HER2 status
 Negative257 (91%)295 (93%)316 (88%)
 Positive26 (9%)22 (7%)42 (12%)
Adjuvant chemotherapy
 No283 (100%)317 (100%)243 (68%)
 Yes00115 (32%)
Distant recurrence
 Overall56 (100%)33 (100%)57 (100%)
 Early (≤5 y)27 (48%)13 (39%)34 (60%)
 Late (>5 y)29 (52%)20 (61%)23 (40%)
BCI groups
 Low156 (55%)202 (64%)196 (55%)
 Intermediate75 (27%)65 (20%)78 (22%)
 High52 (18%)50 (16%)84 (23%)

Abbreviation: NA, not available.